Mesenchymal stem cells (MSCs) and MSC-derived tissue engineered bone grafts (TEBGs)
are increasingly being used in the treatment of fractures. However, the influence
of tissue culture in vitro on their potency, in particular, the mechanistic understanding of how osteogenic
priming enhances reparative efficacy of MSC-based TEBGs remains unclear. Here we hypothesize
that osteogenic priming not only triggers the differentiation of MSCs, but also alters
the secretion of growth factors and cytokines critical for bone repair. Accordingly,
we generated TEBGs with human primitive fetal MSCs loaded macroporous scaffolds which
were dynamically cultured and osteogenically primed in biaxial rotating bioreactor
systems, and studied their resulting secretome, as well as their ability to heal a
critical-sized rat femoral defect. Results from protein analysis showed that highly-differentiated
MSCs secreted significantly higher level of angiogenic growth factors, compared with
MSCs which were primed from a shorter duration of time or non at all. Furthermore,
in vivo bone healing also benefited from pre-transplant osteogenic induction on the cellular
constructs. Radiographic images showed that the rats implanted with highly induced
constructs achieved the best bone repair with significantly more neo-vasculogenesis,
which also suggested that the TEBGs’ healing capacity might be enhanced primarily
through amplified paracrine effects, rather than by improved functional engraftment.
Taken together, osteogenic induction alters primitive fetal MSCs’ secretomes and improves
their healing capacities. Our study indicates the value of conducting osteogenic priming
on MSC-based TEBGs for healing bone defects, and may shed light on the optimal strategy
to prepare clinically relevant TEBGs.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
28
Identification
Copyright
© 2015 Published by Elsevier Inc.